Study Stopped
Funding expired
Amblyopia and Strabismus Detection Using Retinal Birefringence Imaging
RBI
Deploying Retinal Birefringence Imaging in to the Clinic for Pediatric Vision Screening
1 other identifier
observational
N/A
1 country
1
Brief Summary
The purpose of this project is to compare the accuracy of two products at detecting amblyopia and strabismus in children. The devices will be Rebiscan's "blinq" (Pediatric Vision Scanner; PVS) and Rebiscan's RBI (Retinal Birefringence Imager).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
Started Feb 2020
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 16, 2019
CompletedFirst Posted
Study publicly available on registry
April 18, 2019
CompletedStudy Start
First participant enrolled
February 4, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 31, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
May 31, 2023
CompletedNovember 18, 2023
November 1, 2023
3.3 years
April 16, 2019
November 16, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
Presence of amblyopia / strabismus
Readouts of RBI device will be compared to clinical examination results
1 single day
Study Arms (2)
Enriched Population
Children between the ages of 2-8 who present to an eye clinic. Eligible and recruited children will be scanned with a PVS device and an RBI device, and then be provided with a full, gold standard eye exam by a pediatric ophthalmologist. All scans and exam should be performed within a single visit. Scans should take no longer than 20 seconds each, and ophthalmic exam should take approximately 30 minutes.
Unenriched Population
Children between the ages of 2-8 who present to a general pediatric clinic, with no history of eye disorders or amblyopia. Eligible and recruited children will be scanned with a PVS device and an RBI device, and then be provided with a full, gold standard eye exam by a pediatric ophthalmologist. All scans will be performed at a single visit, but the exam may require a follow up visit, depending on the availability of a pediatric ophthalmologist at the clinic at the time of study enrollment. Scans should take no longer than 20 seconds each, and ophthalmic exam should take approximately 30 minutes.
Interventions
Device is a hand-help object approximately the size of a brick, and is held, by the user, 30cm away from the patient/subject. The subject peers in to an aperture that includes a fixation target that is in the shape of a smiley face. During this time, a ring of LED lights illuminates the eye and captures an image of the retina in approximately 3 seconds. The results instantaneously identify the presence of amblyopia / strabismus.
Eligibility Criteria
Children between the ages of 2-8, with no gender, race, or ethnicity restricted from enrollment.
You may qualify if:
- Children who present to the participating clinics
- Provide assent
- Guardian provides informed consent
You may not qualify if:
- \- Developmental delay or cognitive deficit
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Rebiscan, Inc.lead
- Retina Foundation of the Southwestcollaborator
Study Sites (1)
Retina Foundation of the Southwest
Dallas, Texas, 75231, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Eileen Birch, PhD
Retina Foundation of the Southwest
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 16, 2019
First Posted
April 18, 2019
Study Start
February 4, 2020
Primary Completion
May 31, 2023
Study Completion
May 31, 2023
Last Updated
November 18, 2023
Record last verified: 2023-11